Marvel Biosciences Corp. (MRVL.V) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-160.0%

-CA$0.07

vs CA$0.12 price

Levered DCF

-CA$0.05

After debt service

Piotroski score

2 / 9

Weak

Altman Z-score

-56.02

Distress zone

Rating

Overall 2 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
P/E	-3.74×	-0×	-1.38×	-1.09×	-2.57×	-3×	-11.85×
P/B	-2.07×	-1.7×	-1.84×	14.24×	3.32×	24.19×	2.81×
P/S	0×	0×	0×	0×	0×	0×	0×
EV / EBITDA	-5.38×	5.03×	-1.61×	-0.86×	-4.35×	-2.6×	-5.58×
Gross margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Operating margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Net margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Current ratio	0.08×	0.31×	0.48×	1.27×	21.94×	1.67×	135.64×
Debt / equity	-0.58×	-0.61×	-0.58×	0×	0×	0×	0×
Interest coverage	-4.66×	-0.01×	-67.04×	-1,642.33×	409.72×	-1,327.12×	0×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
Return on equity	55.2%	0.1%	133.2%	-1306.2%	-129.0%	-804.4%	-23.7%
Return on invested capital	73.6%	0.1%	322.0%	-1301.0%	34.2%	-803.2%	18.2%
Return on assets	-676.9%	-0.3%	-340.8%	-279.6%	-123.1%	-322.9%	-23.5%
Free cash flow yield	-13.9%	-24.6%	-42.0%	-78.8%	-17.5%	-18.7%	-3.6%
Earnings yield	-26.7%	-0.0%	-72.2%	-91.7%	-38.9%	-33.2%	-8.4%
Enterprise value	CA$10.5M	CA$6.2M	CA$3.6M	CA$2.2M	CA$5.4M	CA$2.6M	CA$1.2M
Net debt / EBITDA	-1.12×	1.12×	-0.2×	0.23×	1.92×	0.22×	0.03×
Cash conversion cycle (days)	-1,000	-1,629	-497	-69	-1	-130	0